BetterRX

BetterRX Competitive Intelligence & Landscape

betterrx.com ·

Overview

BetterRX Overview

BetterRX is a healthcare technology company specializing in pharmacy management solutions, primarily serving hospice care providers. Its core product is hospice pharmacy software designed to streamline medication management, improve care coordination, and reduce costs for hospice organizations (BetterRX). The company's platform facilitates a network of pharmacies, enabling better collaboration and efficiency within hospice care settings (BetterRX Pharmacy Network).

Founded in 2003, BetterRX is headquartered in the United States and has gained recognition as a significant player in healthcare technology, including being named a 2024 Inc. 5000 honoree, which highlights its rapid growth and success (Inc.com). The company’s target market primarily includes hospice providers, healthcare administrators, and pharmacies seeking to optimize medication management and reduce operational costs (BetterRX About Us).

With a mission to improve patient care while lowering healthcare costs, BetterRX aims to transform hospice pharmacy operations through innovative technology solutions. Its value proposition centers on enhancing medication safety, operational efficiency, and care quality for hospice patients, making it a vital resource in the hospice healthcare ecosystem (BetterRX).

BetterRX

BetterRX Weekly Intel Updates

Receive weekly intel updates about BetterRX straight to your inbox.

Competitors

BetterRX Competitors

OrderBoard is a notable competitor to BetterRX, primarily distinguished by its focus on healthcare practice management and appointment scheduling solutions. It caters to outpatient clinics and healthcare providers, offering features that streamline patient flow and operational efficiency. Compared to BetterRX, which emphasizes pharmacy and prescription management, OrderBoard's market positioning is more aligned with practice automation, and its revenue and market share reflect a different niche within healthcare technology (Growjo).

PracticeSuite is another key competitor, known for its comprehensive EHR (Electronic Health Records) and practice management software. It targets small to mid-sized healthcare practices and emphasizes affordability and ease of use. PracticeSuite's competitive edge lies in its integrated billing and scheduling features, which may differ from BetterRX's pharmacy-centric focus, and it often competes on pricing and feature set for outpatient clinics (ZoomInfo).

EMRFinder and PrognoCIS EHR are also relevant competitors, primarily offering EHR solutions tailored for various healthcare providers. EMRFinder provides drug interaction and medication management tools, positioning itself as a specialized platform for pharmacy and medication-related services. PrognoCIS offers a broad suite of EHR functionalities with a focus on interoperability and compliance, competing with BetterRX in the broader healthcare software market (G2).

PrimeRx emerges as a direct alternative to BetterRX, especially in pharmacy management. It is recognized for its robust medication dispensing features, inventory management, and pricing tools, making it popular among independent pharmacies. PrimeRx's market positioning emphasizes cost-efficiency and comprehensive pharmacy operations, which contrasts with BetterRX's broader healthcare focus (G2).

In summary, BetterRX faces competition from a range of healthcare management and pharmacy software providers, with key differentiators including specialization in pharmacy operations, pricing strategies, and the breadth of integrated features. Market share varies, but companies like PrimeRx and PracticeSuite are notable for their targeted solutions and competitive pricing, positioning them as strong alternatives in the healthcare SaaS landscape (Growjo, G2).

Product & Pricing

BetterRX Product and Pricing Intelligence

BetterRX offers a range of product and pricing plans tailored to different healthcare needs, including pharmacy management, hospice care, and clinical operations. According to their pricing page (BetterRX Pricing), the company provides various tiers, but specific details about the current plans, features, and pricing structures are not explicitly listed in the search results. Typically, these plans include features such as real-time pharmacy solutions, billing integration, and clinical management tools.

While exact recent changes to pricing are not detailed, the company’s blog posts and updates, such as the one published on September 8, 2023, suggest ongoing enhancements to their platform, including billing and connected RX solutions (BetterRX Blog). The platform appears to emphasize flexible, scalable solutions for healthcare providers, with distinctions between free and paid features likely based on the level of service and integrations required.

For precise current pricing tiers, features, and recent updates, visiting the official BetterRX pricing page or contacting their sales team directly would provide the most accurate and up-to-date information, especially given the evolving nature of healthcare technology solutions.

Ad Campaigns

BetterRX Ad Campaigns

BetterRX is currently running 70 ads across LinkedIn — 70 on LinkedIn. Explore BetterRX's live ad creative, messaging, and the platforms they advertise on in the ad library — updated automatically by ForesightIQ.

See of BetterRX's ads

View ads

Hiring & Layoffs

BetterRX Hiring and Layoffs

As of April 2026, BetterRX continues to demonstrate active hiring trends, with recent job openings available across various roles, including sales and technology positions. According to recent listings on ZipRecruiter, the company is currently hiring for around 60 positions, with salaries ranging from $32,000 to $170,000, indicating a broad spectrum of roles and seniority levels (ZipRecruiter). The company's hiring process remains efficient, with an average interview duration of about 12 days, reflecting a streamlined recruitment approach that supports rapid onboarding (Glassdoor).

In terms of strategic signals, BetterRX's ongoing recruitment efforts suggest a focus on expanding its team to support growth in its pharmacy services and technology platforms. The company's emphasis on a mission-driven culture and growth opportunities, as highlighted on their careers page, indicates a strategic intent to attract talent aligned with their healthcare and technology integration goals (BetterRX Careers).

Regarding layoffs, there are no recent reports or indications of significant layoffs at BetterRX, which suggests stability in their workforce and a positive outlook on their operational and strategic trajectory. The company's continued hiring and stable employment environment imply a focus on scaling their services and enhancing their healthcare technology solutions without major workforce reductions.

Leadership

BetterRX Management and Leadership Team

As of April 2026, BetterRX has undergone significant leadership developments. The company appointed Tim Tannert as CEO in July 2025, following a strategic investment from BVP Forge aimed at transforming hospice pharmacy care nationwide (Business Wire). Additionally, Marcus Wilson was welcomed as the company's first Chief Pharmacy Officer in 2025, indicating a focus on strengthening pharmacy leadership (Homecare Magazine).

Regarding the broader management and leadership team, detailed information about other key executives and recent leadership changes is available through sources like The Org and SignalHire, which profile company leadership (The Org, SignalHire). While specific names of other board members and notable hires at the C-suite level are not explicitly listed in the recent search results, the company's strategic moves and leadership appointments suggest a focus on expanding its executive team to support its growth in hospice pharmacy services.

Financials

BetterRX Financial Performance, Fundraising, M&A

As of April 2026, BetterRX has demonstrated strong financial growth and active fundraising efforts. According to recent reports, the company received a growth investment from BVP Forge in July 2025, which indicates ongoing investor confidence and support for its expansion (FinSMEs). While specific revenue figures are not explicitly detailed in the available sources, BetterRX's inclusion in the Inc. 5000 list again in 2025 highlights its rapid growth and increasing market presence (Business Wire).

Funding rounds include a notable capital raise on July 28, 2025, which further supports its financial health and expansion strategies (Gaebler.com). Although precise valuation figures are not publicly available, the company's consistent recognition and recent investments suggest a strong valuation trajectory. Additionally, BetterRX has engaged in acquisitions and strategic growth initiatives, positioning itself as a significant player in healthcare technology and pharmacy benefit management sectors (PrivCo). Overall, BetterRX's financial health appears robust, supported by recent funding, growth awards, and strategic investments.

Partnerships

BetterRX Partnerships, Clients and Vendors

BetterRX has established a robust network of partnerships, clients, and vendors within the healthcare and hospice pharmacy sectors. Notable collaborations include strategic integrations with major healthcare technology providers such as MatrixCare and Netsmart, which are prominent in electronic health record (EHR) and healthcare management systems (BetterRX + MatrixCare, BetterRX + Netsmart). These partnerships facilitate seamless medication management and pharmacy services integration, enhancing operational efficiency for healthcare providers.

In addition to technology integrations, BetterRX has formed strategic alliances aimed at reducing pharmacy costs and improving hospice care. For instance, their partnership with Hospice Dynamix focuses on cost reduction strategies for hospice agencies, as announced in 2024 (BetterRX and Hospice Dynamix). This collaboration underscores BetterRX’s role in optimizing pharmacy operations and cost management within hospice care.

Furthermore, BetterRX has received significant strategic investment from BVP Forge in 2025, which aims to transform hospice pharmacy care nationwide and indicates ongoing growth and expansion in their ecosystem (BVP Forge Investment). Their client base includes various healthcare providers and hospice agencies, positioning BetterRX as a key player in pharmacy technology solutions for the healthcare industry.

Events

BetterRX Event Participations

BetterRX actively participates in various industry events, conferences, and webinars to showcase its solutions and engage with the healthcare community. Notably, they attended the 2025 National Alliance for Care at Home Annual Conference and Expo, which highlights their involvement in caregiver support and home healthcare sectors (source). Additionally, they were present at the 2024 NAHC Financial Management Conference, emphasizing their focus on financial aspects of healthcare services (source).

Beyond conferences, BetterRX is engaged in hosting and participating in webinars and community events, such as the webinar titled "Enhancing Hospice Care Through Real-Time Medication Management" in collaboration with WorldView, which was recorded and shared for broader educational purposes (source).

For more detailed information on their upcoming and past events, including webinars, trade shows, and community initiatives, visit their official events page (source). This demonstrates their ongoing commitment to industry engagement and thought leadership in medication management and hospice care.

Frequently Asked Questions

What does BetterRX's July 2025 CEO appointment and simultaneous BVP Forge investment signal about where the company is heading?

The dual move — bringing in Tim Tannert as CEO at the same moment BVP Forge closed a growth investment — strongly suggests BetterRX is entering a deliberate scale-up phase rather than an organic drift. Private equity-linked growth investments typically come with board-level mandates for accelerated revenue growth, geographic expansion, or M&A activity, and pairing that capital with a new CEO indicates the prior leadership team was not the vehicle for that next chapter. The company's back-to-back Inc. 5000 appearances in 2024 and 2025 provide the growth narrative that justified the investment thesis.

What does BetterRX's appointment of its first-ever Chief Pharmacy Officer in 2025 reveal about product or operational gaps it is trying to close?

Hiring Marcus Wilson as BetterRX's first Chief Pharmacy Officer signals the company recognized it lacked dedicated clinical pharmacy leadership at the executive level — a meaningful gap for a firm whose core value proposition is hospice pharmacy management. The timing, concurrent with the BVP Forge investment and CEO transition, suggests investors and the incoming CEO identified clinical credibility and pharmacy operations depth as prerequisites for enterprise sales and regulatory trust. This hire is likely intended to strengthen relationships with pharmacies in BetterRX's network and lend authority to clinical product decisions.

With roughly 60 open roles spanning $32K–$170K salaries, what does BetterRX's current hiring footprint suggest about where it is investing for growth?

A 60-role open headcount across a salary band that wide indicates BetterRX is hiring across multiple layers simultaneously — from frontline operational staff to senior sales and technical talent — rather than filling a single strategic gap. The upper end of the range ($170K) points to senior engineering or enterprise sales hires consistent with a post-investment push to build out a scalable platform. The absence of any reported layoffs alongside this hiring volume reinforces that this is expansion, not restructuring.

BetterRX has been named to the Inc. 5000 in both 2024 and 2025 — does that trajectory suggest durable competitive advantage or a growth rate that may be hard to sustain?

Back-to-back Inc. 5000 recognition indicates BetterRX has maintained above-average revenue growth rates over at least a two-year window, which in a niche like hospice pharmacy software is notable given the limited addressable market size. However, Inc. 5000 rankings measure revenue growth rate, not profitability or market share, so they are a momentum signal rather than a valuation anchor. The BVP Forge growth investment arriving alongside the 2025 recognition suggests external capital is being deployed to extend that trajectory into adjacent markets or M&A before organic growth naturally decelerates.

What does BetterRX's partnership with MatrixCare and Netsmart signal about its go-to-market strategy within hospice care?

Integrating with MatrixCare and Netsmart — the two dominant EHR and care-management platforms serving post-acute and hospice providers — tells you BetterRX is pursuing an embedded, ecosystem-dependent distribution model rather than a direct standalone sale. Hospice operators already running MatrixCare or Netsmart can adopt BetterRX with minimal workflow disruption, which lowers the switching cost for the buyer and raises BetterRX's stickiness once installed. This strategy limits BetterRX's exposure to raw greenfield sales cycles but also makes it somewhat dependent on the continued market leadership of those EHR partners.

The 2024 partnership with Hospice Dynamix focuses explicitly on reducing pharmacy costs for hospice agencies — what does that signal about BetterRX's competitive differentiation?

The Hospice Dynamix partnership signals that BetterRX is positioning cost reduction, not just workflow automation, as a core value proposition — a meaningful strategic choice in a hospice market where pharmacy spend is one of the largest and most variable cost drivers. By aligning with a firm focused on financial optimization for hospice agencies, BetterRX is extending its narrative from technology vendor to ROI partner, which typically shortens enterprise sales cycles and elevates conversation to CFO and finance committee level. This also reinforces the themes BetterRX has been pressing at financial conferences like the 2024 NAHC Financial Management Conference.

How differentiated is BetterRX from competitors like PrimeRx and FrameworkLTC, and does its positioning hold up under scrutiny?

BetterRX's sharpest differentiator is its exclusive focus on the hospice pharmacy workflow — a narrower and more defensible niche than PrimeRx, which targets independent pharmacies broadly, or FrameworkLTC, which serves long-term care pharmacies. That specificity matters because hospice pharmacy involves unique regulatory requirements, controlled substance protocols, and care-coordination needs that general pharmacy software is not optimized for. The risk is that hospice is a relatively small total addressable market, which is likely why BetterRX has been building out integrations with home health and home care platforms — the 2025 National Alliance for Care at Home conference attendance is a visible signal of that adjacency push.

BetterRX co-hosted a hospice-focused webinar with WorldView on real-time medication management — what does content partnership activity like this suggest about its sales motion?

Co-producing educational content with WorldView, a hospice workflow platform, and making it available as a recorded resource indicates BetterRX is using thought leadership and partner co-marketing as a top-of-funnel demand generation tool in a market where buyer trust and clinical credibility are prerequisites. Hospice administrators are typically risk-averse buyers who respond to peer validation and regulatory expertise rather than transactional sales pitches. This type of content partnership also deepens the WorldView relationship in ways that could support deeper commercial integration over time.

BetterRX received a growth investment from BVP Forge in July 2025 — what does the choice of BVP Forge as an investor signal about BetterRX's likely next moves?

BVP Forge is the growth equity arm of Bessemer Venture Partners, which has an established portfolio in healthcare IT and vertical SaaS. A growth equity check at this stage typically carries expectations of defined revenue milestones, potential add-on acquisitions, and preparation for a larger exit — either a strategic sale or a later-stage institutional round. The public announcement language specifically referenced transforming hospice pharmacy care 'nationwide,' which points to geographic or market-penetration expansion as an explicit investment thesis rather than purely product development.

BetterRX's pricing details are not publicly disclosed — what does that opacity signal about its sales process and buyer profile?

The absence of published pricing is consistent with a complex, consultative enterprise sales motion targeting hospice agency decision-makers and pharmacy network operators, where deal size and configuration vary enough to make list pricing impractical and competitively sensitive. It also reflects the norm in healthcare SaaS where compliance requirements, integration complexity, and volume discounts make standardized tiers difficult to publish meaningfully. Analysts benchmarking BetterRX's competitive pricing will need to rely on win/loss interviews or procurement disclosures rather than public rate cards.

BetterRX was founded in 2003 but only recently accelerated — what explains the apparent gap between founding date and growth inflection?

BetterRX operated for roughly two decades in a specialized niche before its Inc. 5000 recognition and growth investment materialized, which is not unusual for vertical healthcare SaaS companies that grow steadily on the back of long-term provider relationships before hitting an inflection point driven by regulatory change, market consolidation, or technology modernization. The hospice care market has expanded significantly under the Medicare Hospice Benefit and the broader shift to value-based care, creating a larger and more urgent buyer base for pharmacy management technology. The combination of market tailwinds, a new CEO, and institutional capital in 2025 suggests BetterRX's current acceleration is structurally different from its prior organic growth pace.

Powered by ForesightIQ · Competitive intelligence from digital exhaust